Business
Ainos Launches New VELDONA Pet Lohas and Soothing Health Supplements, Catalyzing Its Drive to $20M Sales Target
New products support pets' emotional health and allergic responses, hit market in Taiwan following successful launch of VELDONA® PetExpanding VELDONA® Pet
About this update from Ainos, Inc.
[{"type":"text","content":"New products support pets' emotional health and allergic responses, hit market in Taiwan following successful launch of VELDONA® PetExpanding VELDONA® Pet product line builds growth momentum toward US$20M sales target for 2024SAN DIEGO, CA / ACCESSWIRE / June 7, 2023 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) (\"Ainos\", or the \"Company\"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced the launch of two new additions to its VELDONA® Pet cytoprotein supplement product line. VELDONA® Pet Lohas, designed to support pets' emotional health and relieve stress, and VELDONA® Pet Soothing, formulated to relieve discomfort caused by allergies, will be launched in Taiwan in July. Ainos aims for US$20 million in sales from its VELDONA® Pet supplements during 2024, with additional product releases and expansion of sales and marketing in other regions. VELDONA® Pet Lohas contributes to the emotional well-being of dogs and cats, providing relief from stress and discomfort. A study conducted by China Medical University demonstrated that interferon treatments may reduce the risk of depression by aiding in the regulation of cellular inflammatory responses in the brain. Interferon may also positively affect the regeneration and remodeling of synapses between nerve cells in the brain.VELDONA® Pet Soothing normalizes a pet's immune response to allergens by inducing the body's natural regulation mechanism. The product is designed to reduce discomfort and milder allergic symptoms. The effectiveness of interferons in regulating allergic reactions has been found in a study conducted by the National Research Institute of Japan.Both supplements will be marketed in Taiwan beginning next month. Their launch follows closely on the heels of last week's release of Ainos' VELDONA® Pet cytoprotein health supplement, which is currently available to pet owners in Taiwan. Ainos plans to introduce its portfolio of pet products to additional markets in the near future as part of its global business development strategy.Chun-Hsien Tsai, Ainos' Chairman of the Board, President, and Chief Executive Officer, commented, \"The release of our latest VELDONA® Pet supplements is an important milestone in this truly transformational year ...